

May 13, 2009

Exchange Notice

Tailor Made Clearing 08/09

Adjustment in Biophausia due to rights issue

As previously announced, Biophausia's Annual General Meeting (AGM) approved the proposed rights issue (1:8), whereby shareholders are entitled to one (1) unit for every eight (8) shares held. The subscription price per unit is 1.50 SEK. The record date is May 15, 2009. NASDAQ OMX Derivatives Markets has carried out a re-calculation of options and forwards in Biophausia as described below.

Re-calculation of stock option and forwards

Conditions	1:8, issue price 1.50 SEK, distribution of one (1) unit consisting of one (1) call option and one (1) subordinated debenture. See press release from Biophausia for more details.
Ex-date	May 13, 2009
Adjustment factor ¹	$A = \text{VWAP}_{\text{ex}} / \text{VWAP}_{\text{cum}} = 0.9593130$
VWAPcum	1.76564661
VWAPex	1.69380773
New exercise and forward price	Old exercise and forward price * 0.9593130
New contract size	Old contract size / 0.9593130
Date of recalculation	After 19.30 (CET), May 13, 2009
Rules and Regulations of NASDAQ OMX Derivatives Markets	4.5.3.4.2

¹ VWAPcum = volume weighted average price at the day prior to the ex-day (8 decimals are used)

VWAPex = volume weighted average price on the ex-day

New exercise and forwards prices have been rounded off to two decimal places and received an "X" in the series designation. As a result of the adjustment the number of shares per contract has increased to 104 after rounding to the nearest full share, whereas exercise and forward prices have decreased. The series will also receive new ISIN-codes. The rounding off of forward prices was made "trade by trade" and not on the net position.

Members are encouraged to ensure that clients are aware of the above-mentioned adjustment.

For further information concerning this exchange notice please contact Tomas Rinaldo or Håkan Walden, telephone +46 8 405 60 00

NASDAQ OMX Derivatives Markets

Tomas Rinaldo
Derivatives Analyst

Håkan Walden
Jr. Derivatives Analyst